


 Cite this: *RSC Adv.*, 2021, 11, 1050

 Received 1st December 2020
 Accepted 18th December 2020

DOI: 10.1039/d0ra10127c

rsc.li/rsc-advances

Traceless solid-phase synthesis and β -turn propensity of 1,3-thiazole-based peptidomimetics†

 Aizhan Abdildinova  and Young-Dae Gong *

The design and solid-phase synthesis of 1,3-thiazole-based peptidomimetic molecules is described. The solid-phase synthesis was based on the utilization of a traceless linker strategy. The synthesis starts from the conversion of chloromethyl polystyrene resin to the resin with a sulfur linker unit. The key intermediate 4-amino-thiazole-5-carboxylic acid resin is prepared in three steps from Merrifield resin. The amide coupling proceeded at the C4 and C5 positions *via* an Fmoc solid-phase peptide synthesis strategy. After cleavage, the final compounds were obtained in moderate yields (average 9%, 11-step overall yields) with high purities ($\geq 87\%$). Geometric measurements of $C\alpha$ distances and dihedral angles along with an rmsd of 0.5434 for attachment with $C\alpha$ of the β -turn template suggest type IV β -turn structural motifs. Additionally, the physicochemical properties of the molecules have been evaluated.

Introduction

Protein–protein interactions (PPIs) are involved in numerous biological processes at the cellular level, such as signal transduction, cell adhesion, cellular proliferation, growth, and programmed cell death.^{1,2} Thus, PPI regulators represent an attractive target for the development of new-generation therapeutics.³ Proteins bind to each other through a combination of hydrophobic bonding, van der Waals forces, and salt bridges at specific binding domains on each protein.⁴ The binding sites are often called hot-spot regions and represent key amino acid residues involved in the binding. The development of PPI modulators is based on structural features of hot-spot regions that are generally defined by secondary structural motifs such as turns, helices, and sheets. Efficient structure-based mimicking of hot-spot regions for the PPI modulation is a challenging research goal. Since PPIs often involve protein surfaces of 800–2000 Å², small-molecule libraries show low hit rates after screening.³ Therefore, the development of compounds with higher molecular weight and large surfaces like peptides or natural product derivatives with greater structural diversity is preferred. However, even with improved medicinal properties, peptides are still limited by rapid proteolysis, poor membrane permeability, and low bioavailability.⁵ To solve those complications, several approaches, including peptidomimetic molecules, have been developed.^{6–10} Previously, our research team was interested in the development of

peptidomimetic hybrid molecules containing both small-molecule and peptide moieties.^{1,11}


In continuation of our studies, we present a modified synthesis strategy for 1,3-thiazole-based peptidomimetics. The thiazole ring system is present in the core of natural product molecules, such as oriamide, cyclotheonaezazole A, and dendroamide A, and commercial drugs, such as thiamine (vitamin B1), niridazole (anthelmintic), abafungin (anesthetic), and azereonam (antibiotic).^{12–15} With C2, C4, and C5 atoms available for functionalization, thiazole is a perfect template for the construction of peptidomimetic molecules.

Peptidomimetic compounds were prepared *via* a solid-phase synthetic approach. Solid-phase synthesis is an advantageous tool for the construction of compounds from small molecules to peptides.^{16–18} In the previous studies, for the synthesis of heterocycle-based peptidomimetic molecules, we used backbone amide linker (BAL) utility. The introduction of BAL onto Merrifield resin **1** required up to three additional steps and to obtain heterocycle intermediate resins **A** and **C** we performed up to nine steps in total (Scheme 1a).^{1,11} In current work, we utilized a sulfur-based traceless linker. Thereby, the overall number of the reaction steps was reduced and 1,3-thiazole intermediate resin **4** was obtained in three steps (Scheme 1b). Traceless linkers release compounds without a trace of the linker that was used to tether the intermediates during the synthesis.¹⁹ However, by modifying cleavage conditions, those linkers can serve as a multifunctional unit. In our work, traceless cleavage was achieved by the nucleophilic attack of benzylamine derivatives allowing diversification of the thiazole scaffold at the C2 position. Dipeptide chain elongation proceeded on C4 and C5 positions of thiazole thus reducing distances and enhancing the probability of intramolecular hydrogen bonding between two strands. Herein, we present the

Innovative Drug Library Research Center, Department of Chemistry, College of Science, Dongguk University, 30, Pildong-ro 1-gil, Jung-gu, Seoul 04620, Korea. E-mail: ydgong@dongguk.edu

† Electronic supplementary information (ESI) available: IR and 2D NMR data, HRMS and LC/MS spectral data, and computational data. See DOI: 10.1039/d0ra10127c





Scheme 2 Solid-phase synthesis of thiazole-based peptidomimetics.

achieved using benzylamine derivatives. The crude mixture was purified *via* flash column chromatography providing a peptidomimetic library in moderate yields (3.2–16.6% 11-step overall yield) with high purities ($\geq 87\%$, Table 1). Peptidomimetics containing Trp residue showed a mass pattern of oxidized Trp reporting three +4, +16, +32 peaks corresponding to the formation of kynurenine (W_{KYN}), hydroxy-Trp (W_{ox1}), and *N*-formyl kynurenine/dihydroxy-Trp ($W_{\text{NFK}}/W_{\text{ox2}}$), respectively.²⁵ Oxidation of Trp occurred during treatment of resin **10** with mCPBA; therefore, this synthetic route is unsuitable for the synthesis with unprotected amino acids.

Peptidomimetic **12a** was analysed by 2D NMR spectroscopy in DMSO- d_6 (Fig. S2†). TOCSY experiments showed cross-peaks for the 4-OH-Bn-NH coupling network. ROESY experiments showed several NOE cross-peaks at the Gly-Pro region, as well as NOE cross-peaks for the 4-OH-Bn-NH coupling network. These observations indicate that part of **12a** exhibits a turn-type conformation that is stabilized by the intramolecular hydrogen bonding at the Gly-Pro region.

Table 1 Yields and purities of thiazole-based mimetics **12**

No.	R ¹	R ²	R ³	Yield ^a (%)	Purity ^b (%)
12a	Leu	Leu	4OHBn	12.2	≥ 99
12b	Leu	Trp	4OHBn	7.7	≥ 99
12c	Tyr	Phe	4OHBn	16.6	≥ 99
12d	Tyr	Phe	Bn	5.7	87
12e	Tyr	Trp	Bn	3.2	≥ 99

^a 11-step overall yield from Merrifield resin **1** (with a loading capacity of 2.28 mmol g^{-1}). ^b All the purified products were analyzed by LC/MS.

Computational analysis

To analyze potential β -turn conformations, we calculated the geometric features of the representative molecule **12a** *via* Discovery Studio 2017. First, the distances between substituent $C\alpha$ centers ($i, i+1, i+2, i+3$) were calculated and compared with standard deviations proposed by Whitby *et al.*²⁰ As shown in Table 2, the measured distances fall within the proposed ranges including the distance between $C\alpha_i$ and $C\alpha_{i+3}$ of 5.83 Å. The calculated root-mean-square deviation (rmsd) value of 0.5434 Å (recommended ≤ 2 Å) for attachment of three substituent $C\alpha$ centers of the molecule **12a** with three α -carbons of β -turn template demonstrates the high potential of **12a** in mimicking β -turn structural motifs. The type of β -turn was predicted by calculating the φ and ψ dihedral angles of central residues (Table S2, ESI†). The results suggest that synthesized molecules can be classified as a type IV β -turn mimetic.

Additionally, compounds were subjected to the computational calculation of the physicochemical properties such as calculated $A \log P$, calculated pK_a , molecular weight, number of hydrogen bond donors (HBD) and acceptors (HBA), number of rotatable bonds, molecular surface area, and molecular polar surface area (Fig. 2). Lipinski specified that molecular parameters of the compounds are crucial for their bioavailability as a drug. Accordingly, lipophilicity, the parameter responsible for the solubility, expressed in calculated $\log P$ should be no greater than 5, and good absorption or permeation is more likely to occur for compounds with five HBD and ten HBA.²⁶ Those parameters fall within the recommended ranges for the compounds. The number of rotatable bonds is higher than ten which can affect the oral bioavailability.²⁷ Calculated pK_a varied from 1.65 to 9.83 and falls in a typical range of pK_a values.²⁸



Table 2 Energy minimized conformation of the representative molecule 12a: measured distances and rmsd value

Measured C α distances, Å	rmsd = 0.5434 Å
$i, i + 1$	3.82
$i, i + 2$	7.03
$i, i + 3$	5.83
$i + 1, i + 2$	4.94
$i + 1, i + 3$	6.06
$i + 2, i + 3$	3.76

Molecular weight is another important aspect. Although Lipinski's rule suggests molecular weight ≤ 500 Da, the PPI studies of Arkin *et al.* propose the tendency of clinical-stage PPI inhibitors to have a molecular weight ≥ 500 Da, which is suitable for peptidomimetic molecules.²⁹ Molecular surface area and molecular polar surface area are expectedly higher than for small-molecules. Considering larger contact surfaces of PPI hot spots, the broader interaction surface is beneficial.³⁰

Next, for a biological docking evaluation, we conducted virtual screening with human MdmX (HdmX) protein. Mdm2 and MdmX (Hdm2 and HdmX in humans) belong to the Mdm family proteins and are known to negatively regulate the tumor suppressor, p53 protein.^{31–34} In contrast to Mdm2, MdmX has attracted less research interest but the number of studies has increased in recent years. The overexpression of MdmX has

been reported in 40% tumor cell lines.³⁵ Although some Mdm2 inhibitors can bind to MdmX, the structural difference in the p53-binding pockets of the oncoprotein decreases the efficiency of Mdm2 inhibitors against MdmX. Studies reveal a dual role of MdmX including direct inhibition of p53 and enhanced Mdm2-mediated degradation of p53.^{31,35} Therefore, the development of MdmX inhibitors is of therapeutic interest as studies suggest independent MdmX drug development apart from Mdm2 inhibitors.

Studies showed that crucial interaction of the p53 peptide to human MdmX are made by its hydrophobic Phe19, Trp23 and Leu26 residues that form an interface that fills up a hydrophobic pocket of human MdmX with key residues identified as Tyr99 and Met53 (PDB ID 3DAB).³⁶ Additionally, it was reported that β -hairpin can mimic structural features of the helical structure of p53 enabling structural diversity for the p53 peptidomimetics.³⁷ The crystal structure of human MdmX in complex with p53 analogues was reported previously (PDB ID 3FE7). Accordingly, 8-mer peptidomimetic of p53 (Ac-Phe-Met-Aib-Pmp-Trp-Clu-Ac₃c-Leu-NH₂) makes interactions with HdmX in a similar way as p53 at the hydrophobic binding pocket.³⁸ However, structural side-chain reorientations were observed for Leu56, Val52, and Tyr99. Considering those reports, we run molecular docking of 12a with human MdmX. Compound 12a was docked at the binding site of HdmX at the resolution 1.35 Å using Discovery Studio software. In the docked mode, molecule 12a is bound to the hydrophobic pocket of HdmX resulting in major interactions with Tyr99, Met53, and Leu 98, which is in agreement with previous studies (Fig. 3). Accordingly, Pro of 12a fills the pocket and enters into hydrophobic bonding with Met53, Leu98, and Val92 of HdmX; while Leu binds *via* pi-alkyl and alkyl interactions with Tyr66, Ile60, and Met61 on the other side. N-terminal Leu of 12a binds to the target protein through hydrophobic interactions with Val92 and Lys93 and conventional hydrogen bonding with Gln71.




Fig. 2 Physicochemical properties in bar charts: calculated A log *P*, molecular weight (Da), number of HBD and HBA, number of rotatable bonds, molecular surface area (Å²), and molecular polar surface area (Å²).




Fig. 3 Superimposed view of molecule 12a binding to the active site of HdmX (PDB ID: 3FE7) at a resolution 1.35 Å (conventional hydrogen bond, carbon hydrogen bond, pi-alkyl and alkyl interactions in green, light green, and pink respectively).



Additionally, the secondary amine at the R3 position makes carbon hydrogen bonding with Tyr99.

Conclusions

In conclusion, we established an accessible traceless solid-phase synthesis methodology for the thiazole-based peptidomimetics. The thiazole core incorporated with L-Pro was used as a peptidomimetic template. The key intermediate, 1,3-thiazole with amine and ester functional groups at positions C4 and C5 respectively, was prepared by cyclization of cyanocarbonimidodithioate intermediate resin with an α -bromo ketone. Peptide chain elongations proceeded on both C-terminal and N-terminal sites of the ethyl 4-aminothiazole-5-carboxylate core. Oxidation with further cleavage afforded final compounds in moderate yields and high purities. 2D NMR studies of **12a** showed a part of **12a** exhibits a turn-type conformation that is stabilized by the intramolecular hydrogen bonding at the Gly-Pro region. The geometric characterization of the molecules including C α carbon distances, angles, and rmsd value suggests a type IV β -turn mimetic structure. Calculations of physico-chemical properties showed molecular diversity and suitability of the compounds as PPIs inhibitors. Finally, the representative molecule **12a** was subjected to computational molecular docking to check its potential as a regulator of HdmX/p53 PPIs. The predicted binding poses suggest that the peptidomimetic molecule interacts with the HdmX binding site similar to p53 *via* hydrophobic and hydrogen bond interactions between key residues such as Leu, Phe, and Trp. We believe that the tools and strategies developed in this work will facilitate the development of new peptidomimetic molecules and plan to conduct further studies in the future.

Experimental section

General synthetic methods

All chemicals were of reagent grade and used as purchased. The Merrifield resin was used in 100–200 mesh beads with a loading capacity of 2.28 mmol g⁻¹. The solution phase reactions were monitored by TLC (thin-layer chromatography) analysis using Merck silica gel 60 F-254 thin-layer plates. The solid-phase reactions were monitored using an ATR-FTIR spectrometer (Smiths Detection Group Ltd). The crude product mixtures were purified with a flash chromatography system using Isolera One (Biotage). Flash column chromatography was carried out on Merck silica gel 60 (230–400 mesh). NMR analysis was recorded in δ units relative to deuterated solvent as an internal reference using a 500 MHz NMR spectrometer (Bruker). Liquid chromatography-tandem mass spectrometry was performed using electrospray ionization (ESI) with a photodiode array detector (PDA) *via* 6460 Triple Quad LC/MS (Agilent). High-resolution mass spectrometry was performed using a Q6550 iFunnel Q-TOF LC/MS system (Agilent).

Representative procedure for the synthesis of cyanocarbonimidodithioate resin 2. Potassium cyanocarbonimidodithioate (15.5 g, 80 mmol) was added to a suspension of Merrifield resin **1** (8.77 g, 20 mmol) in DMF (60 mL) at 0 °C.

Potassium cyanocarbonimidodithioate was prepared as described in the published literature.²⁴ The reaction mixture was shaken for 6 h and RT. Cyanocarbonimidodithioate resin **2** was filtered and washed successively with DMF, H₂O, DCM ($\times 2$), and MeOH ($\times 2$), and dried under high vacuum. The resulting yield of the resin **2** was 12.4 g; single-bead ATR-FTIR $\nu_{\max}/\text{cm}^{-1}$: 3443, 2920, 2160 (C \equiv N), 1653 (C=N), 1369, 1096, 1059, 943, 758, 697, 661.

Representative procedure for the preparation of ethyl 4-amino-1,3-thiazole-5-carboxylate resin 3. Ethyl bromoacetate (3.33 mL, 30 mmol) and TEA (4.3 mL, 30 mmol) were added to a suspension of cyanocarbonimidodithioate resin **2** (4.39 g, 10 mmol) in DMF (50 mL). The reaction mixture was shaken at 60 °C for 6 h. The resin was cooled to RT, filtered and washed successively with DMF, MeOH ($\times 2$), and DCM ($\times 2$), and dried under high vacuum. The resulting yield of the resin **3** was 4.29 g; single-bead ATR-FTIR $\nu_{\max}/\text{cm}^{-1}$: 3478 and 3365 (NH), 2921, 2102, 1664 (CO), 1595, 1375, 1296 (CO-O), 1123 (CO-O), 1083, 760, 697.

Representative procedure for the preparation of 4-amino-1,3-thiazole-5-carboxylic acid resin 4. The suspension of ethyl 4-amino-1,3-thiazole-5-carboxylate resin **3** (5 g, 11.4 mmol) in THF:EtOH (1 : 1, v/v, 46 mL) was reacted with 5 M NaOH (45.6 mL, 228 mmol). The reaction mixture was shaken for 24 h at 60 °C. The resin was cooled to RT, filtered and washed successively with THF, H₂O, MeOH, and DCM several times, and dried under high vacuum. The resulting yield of the resin **4** was 4.74 g; single-bead ATR-FTIR $\nu_{\max}/\text{cm}^{-1}$: 3332 (OH), 2918, 2102, 1559, 1491, 1375, 1339, 1240, 1064, 794, 757, 696.

Representative procedure for C-terminal amide coupling: preparation of the resin 5. To a suspension of resin **4** (2.19 g, 5 mmol) in DMF (15 mL) HBTU (5.69 g, 15 mmol), and HOBT hydrate (2.02 g, 15 mmol) were added respectively. The mixture was shaken for 15 min. In a separate flask, L-proline methyl ester hydrochloride (2.48 g, 15 mmol) was dissolved in DMF (5 mL), followed by the addition of DIPEA (4.35 mL, 25 mmol). The activated amino acid was added to the resin suspension after stirring for 15 min, and the reaction mixture was shaken for 24 h at RT. The resin was filtered and washed successively with DMF, H₂O, DCM, MeOH several times, and dried under a high vacuum. The resulting yield of the resin **5** was 2.33 g; single-bead ATR-FTIR $\nu_{\max}/\text{cm}^{-1}$: 3473 and 3330 (NH), 2918, 2102, 1738 (CO), 1578, 1491, 1400, 1197 (CO-O), 1172 (CO-O), 840, 752, 697.

Representative procedure for the preparation of resin 6. The suspension of ethyl 4-amino-1,3-thiazole-5-carboxylate resin **5** (2.33 g, 5 mmol) in THF : EtOH (1 : 1, v/v, 20 mL) was reacted with 5 M NaOH (20 mL, 100 mmol). The reaction mixture was shaken for 7 h at 60 °C. The resin was cooled to RT, filtered and washed successively with THF, H₂O, MeOH, and DCM several times, and dried under high vacuum. The resulting yield of the resin **6** was 2.09 g; single-bead ATR-FTIR $\nu_{\max}/\text{cm}^{-1}$: 3342 (OH), 2920, 2105, 1698 (CO), 1573, 1507, 1491, 752, 696.

Preparation of resin 7. The resin **7** was prepared from resin **6** according to the C-terminal amide coupling procedure. **7a** single-bead ATR-FTIR $\nu_{\max}/\text{cm}^{-1}$: 2916, 2102, 1738 (CO), 1703 (CO), 1673 (CO), 1587, 1505, 1491, 1384, 753, 597.



Representative procedure for the acylation reaction

Solution phase synthesis of compound C. Amino ester thiazole **A** was synthesized according to the known procedure.²⁴ To the mixture of **A** (0.029 g, 0.1 mmol) in 1,4-dioxane (4 mL) K_2CO_3 (0.042 g, 0.3 mmol) and Fmoc-Gly-Cl (0.095 g, 0.3 mmol) were added. The reaction mixture was stirred at 80 °C and monitored by TLC. After 14 h, the reaction was completed. The reaction mixture was cooled to RT and diluted with ethyl acetate, washed with H_2O . The organic layer was dried with anhydrous $MgSO_4$ and evaporated. The crude mixture was purified by column chromatography on silica gel ethyl acetate/hexanes (4 : 1, v/v) affording desired product ethyl 4-(2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)acetamido)-2-(benzylthio)thiazole-5-carboxylate **C** (0.045 g, 78% yield). LC-MS (ESI): $m/z = 574.2 [M + H]^+$. HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{30}H_{27}N_3O_5S_2$ 574.1465; found 574.1456.

Solid-phase synthesis of resin 8a. The suspension of resin **7a** (0.45 g, theoretically 1 mmol) in 1,4-dioxane (7 mL) was reacted with K_2CO_3 (0.55 g, 4 mmol) and Fmoc-Gly-Cl (0.94 g, 3 mmol). The reaction mixture was gently stirred at 80 °C for 24 h. The resin was cooled to RT, filtered and washed successively with DMF, H_2O , MeOH, and DCM several times, and dried under high vacuum. The resulting yield of the resin **8a** was 0.46 g; single-bead ATR-FTIR ν_{max}/cm^{-1} : 2920, 2090, 1703 (CO), 1623, 1507, 1491, 1449, 828, 757, 740, 697.

Representative procedure for the removal of Fmoc-protecting group: synthesis of resin 9a. The resin **8a** (0.46 g, theoretically 1 mmol) was reacted with 20% piperidine in DMF (5 mL), and the mixture was shaken for 3×30 min at RT. The resin was washed with DMF ($\times 2$) and DCM ($\times 2$) and dried under high vacuum. The resulting yield of the resin **9a** was 0.41 g.

Representative procedure for N-terminal amide coupling: preparation of resin 10a. The suspension of resin **9a** (0.2 g, theoretically 0.5 mmol) in DMF (3 mL) was reacted with DIPEA (0.4 mL, 2.25 mmol), and the reaction mixture was shaken at RT for 15 min. In a separate flask, *N*-acetyl-L-leucine was dissolved in DMF (2 mL) and reacted with EDC·HCl (0.23 g, 1.35 mmol), and HOBt (0.18 g, 1.35 mmol). The reaction mixture was stirred for 15 min. The two mixtures were combined and vortexed for 24 h at RT. The resin was filtered and washed successively with DMF, H_2O , DCM, and MeOH, and dried under high vacuum. The resulting yield of the resin **10a** was 0.213 g.

Representative procedure for the oxidation step: preparation of resin 11a. The suspension of resin **10a** (0.213 g, theoretically 0.5 mmol) in DCM (5 mL) was treated with mCPBA (0.24 g, 1.1 mmol) and shaken for 4 h at RT. The resin was filtered and washed successively with DCM and MeOH repeatedly and dried under a high vacuum. The resulting yield of the resin **11a** was 0.223 g.

Representative procedure for cleavage from the resin: preparation of the methyl (4-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-2-((4-hydroxybenzyl)amino)thiazole-5-carbonyl)-L-prolyl-L-leucinate 12a. The resin **11a** (0.223 g, 0.5 mmol) in 1,4-dioxane was reacted with 4-hydroxybenzyl amine (0.123 g, 1 mmol) and TEA (0.2 mL, 1.5 mmol). The reaction

mixture was shaken at 60 °C overnight, followed by cooling to RT. The resin was filtered and washed with DCM and MeOH (15 mL). The organic filtrate was collected and evaporated. The crude mixture was purified *via* column chromatography DCM/MeOH (9 : 1, v/v) and dried under high vacuum to obtain a beige-colored solid (43 mg, 12.2%, 11-step overall yield): LC-MS (ESI): $m/z = 702.4 [M + H]^+$. HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{33}H_{47}N_7O_8S$ 702.3280; found 702.3273.

Methyl (4-(2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)acetamido)-2-((4-hydroxybenzyl)amino)thiazole-5-carbonyl)-L-prolyl-L-leucinate 12b. (30 mg, 7.7%): LC-MS (ESI): $m/z = 807.4 [M + H]^+$ (W_{NFK}). HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{38}H_{46}N_8O_8S$ 775.3232; found 779.3151 (W_{KYN} , +4 Da), 791.3159 (W_{ox1} , +16 Da), 807.3115 (W_{NFK} , +32 Da).

Ethyl (4-(2-((S)-2-acetamido-3-phenylpropanamido)acetamido)-2-((4-hydroxybenzyl)amino)thiazole-5-carbonyl)-L-prolyl-L-tyrosinate 12c. (65 mg, 16.6%): LC-MS (ESI): $m/z = 786.3 [M + H]^+$. HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{39}H_{43}N_7O_9S$ 786.2916; found 786.2895.

Methyl (4-(2-((S)-2-acetamido-3-phenylpropanamido)acetamido)-2-(benzylamino)thiazole-5-carbonyl)-L-prolyl-L-tyrosinate 12d. (22 mg, 5.7%): LC-MS (ESI): $m/z = 770.3 [M + H]^+$. HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{39}H_{43}N_7O_8S$ 770.2967; found 770.2959.

Methyl (4-(2-((S)-2-acetamido-3-(1H-indol-2-yl)propanamido)acetamido)-2-(benzylamino)thiazole-5-carbonyl)-L-prolyl-L-tyrosinate 12e. (13 mg, 3.2%): LC-MS (ESI): $m/z = 841.3 [M + H]^+$ (W_{NFK}). HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{41}H_{44}N_8O_8S$ 809.3075; found 813.3305 (W_{KYN} , +4 Da), 827.3148 (W_{ox1} , +16 Da), 841.2958 (W_{NFK} , +32 Da).

Computational studies

The molecular docking study of the library was performed *via* Discovery Studio 2017 (BIOVIA) at the binding site of HdmX (PDB code 3FE7) at a resolution of 1.35 Å. Flexible docking was performed *via* CDOCKER docking protocol with the CHARMM force field. Ligands were subjected to full energy minimization and docked with tautomerization and isomerization features off. The most energetically favorable conformation for the top hit was set to 1 for each molecule. Docking results were analyzed according to -CDOCKER energy: the molecule with the highest -CDOCKER energy is considered as the most suitable ligand for the target molecule.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

All authors were supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2016R1D1A1B04932654).



References

- 1 A. Abdildinova, S.-J. Yang and Y.-D. Gong, *Tetrahedron*, 2018, **74**, 684–691.
- 2 L. G. Milroy, T. N. Grossmann, S. Hennig, L. Brunsveld and C. Ottmann, *Chem. Rev.*, 2014, **114**, 4695–4748.
- 3 M. Pelay-Gimeno, A. Glas, O. Koch and T. N. Grossmann, *Angew. Chem., Int. Ed. Engl.*, 2015, **54**, 8896–8927.
- 4 L. Nevola and E. Giralt, *Chem. Commun.*, 2015, **51**, 3302–3315.
- 5 N. Qvit, S. J. S. Rubin, T. J. Urban, D. Mochly-Rosen and E. R. Gross, *Drug Discovery Today*, 2017, **22**, 454–462.
- 6 J. Vagner, H. Qu and V. J. Hruby, *Curr. Opin. Chem. Biol.*, 2008, **12**, 292–296.
- 7 L. Mabonga and A. P. Kappo, *Int. J. Pept. Res. Ther.*, 2019, **26**, 225–241.
- 8 M. S. Kumar, *Front. Nutr.*, 2019, **6**, 11.
- 9 G. R. Marshall and F. Ballante, *Drug Dev. Res.*, 2017, **78**, 245–267.
- 10 E. Lenci and A. Trabocchi, *Chem. Soc. Rev.*, 2020, **49**, 3262–3277.
- 11 M.-J. Cha, A. Abdildinova and Y.-D. Gong, *Tetrahedron*, 2020, 131702, DOI: 10.1016/j.tet.2020.131702.
- 12 M. Gümüş, M. Yakan and İ. Koca, *Future Med. Chem.*, 2019, **11**, 1979–1998.
- 13 S. J. Kashyap, V. K. Garg, P. K. Sharma, N. Kumar, R. Dudhe and J. K. Gupta, *Med. Chem. Res.*, 2011, **21**, 2123–2132.
- 14 M. V. N. de Souza, *J. Sulfur Chem.*, 2005, **26**, 429–449.
- 15 S. Pola, in *Scope of Selective Heterocycles from Organic and Pharmaceutical Perspective*, 2016, ch. 1, DOI: 10.5772/62077.
- 16 J. M. Palomo, *RSC Adv.*, 2014, **4**, 32658–32672.
- 17 J.-A. F. Muriel Amblard, J. Martinez and G. Subra, *Mol. Biotechnol.*, 2006, **33**, 239–254.
- 18 V. Made, S. Els-Heindl and A. G. Beck-Sickinger, *Beilstein J. Org. Chem.*, 2014, **10**, 1197–1212.
- 19 N. Cankarova, E. Schutznerova and V. Krchnak, *Chem. Rev.*, 2019, **119**, 12089–12207.
- 20 L. R. Whitby, Y. Ando, V. Setola, P. K. Vogt, B. L. Roth and D. L. Boger, *J. Am. Chem. Soc.*, 2011, **133**, 10184–10194.
- 21 A. J. Metrano, N. C. Abascal, B. Q. Mercado, E. K. Paulson, A. E. Hurltley and S. J. Miller, *J. Am. Chem. Soc.*, 2017, **139**, 492–516.
- 22 P. Kountouris and J. D. Hirst, *BMC Bioinf.*, 2010, **11**, 407.
- 23 B. Eckhardt, W. Grosse, L. O. Essen and A. Geyer, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 18336–18341.
- 24 T. Lee, J.-H. Park, M.-K. Jeon and Y.-D. Gong, *J. Comb. Chem.*, 2009, **11**, 288–293.
- 25 I. Perdivara, L. J. Deterding, M. Przybylski and K. B. Tomer, *J. Am. Soc. Mass Spectrom.*, 2010, **21**, 1114–1117.
- 26 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, *Adv. Drug Delivery Rev.*, 1997, **23**, 3–25.
- 27 D. F. Veber, S. R. Johnson, H.-Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, *J. Med. Chem.*, 2002, **45**, 2615–2623.
- 28 D. T. Manallack, *Perspect. Med. Chem.*, 2007, **1**, 25–38.
- 29 M. R. Arkin, Y. Tang and J. A. Wells, *Chem. Biol.*, 2014, **21**, 1102–1114.
- 30 M. C. Smith and J. E. Gestwicki, *Expert Rev. Mol. Med.*, 2012, **14**, e16.
- 31 G. Sanz, M. Singh, S. Peugeot and G. Selivanova, *J. Mol. Cell Biol.*, 2019, **11**, 586–599.
- 32 A. Czarna, G. M. Popowicz, A. Pecak, S. Wolf, G. Dubin and T. A. Holak, *Cell Cycle*, 2009, **8**, 1176–1184.
- 33 M. Wade, Y. C. Li and G. M. Wahl, *Nat. Rev. Cancer*, 2013, **13**, 83–96.
- 34 K. Lenos and A. G. Jochemsen, *J. Biomed. Biotechnol.*, 2011, **2011**, 876173.
- 35 A. Macchiarulo, N. Giacchè, A. Carotti, F. Moretti and R. Pellicciari, *RSC Med. Chem.*, 2011, **2**, 455–465.
- 36 G. M. Popowicz, A. Czarna and T. A. Holak, *Cell Cycle*, 2008, **7**, 2441–2443.
- 37 R. Fasan, R. L. Dias, K. Moehle, O. Zerbe, D. Obrecht, P. R. Mittl, M. G. Grutter and J. A. Robinson, *Chembiochem*, 2006, **7**, 515–526.
- 38 J. Kallen, A. Goepfert, A. Blechschmidt, A. Izaac, M. Geiser, G. Tavares, P. Ramage, P. Furet, K. Masuya and J. Lisztwan, *J. Biol. Chem.*, 2009, **284**, 8812–8821.

